Keyword: Johnson & Johnson


Johnson & Johnson to Acquire Ambrx

09.01.2024 -

Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology...


Johnson & Johnson Receives Two Cancer Drug Approvals

11.08.2023 -

The US FDA approved Akeega and Talvey late last week. Phase 3 trials validated Akeega's use in the treatment of patients with BRCA-positive prostate cancer. Talvey is...


Plaintiffs Reject newest J&J Talc Litigation Offer

06.04.2023 -

Seeking to clear billions of dollars worth of litigation claiming that its iconic baby powder causes cancer, Johnson & Johnson has announced it is now prepared to offer a...


J&J Fights to Save Lawsuit-dodging Runoff Company

24.03.2023 -

After failing yet again this week to overturn a judgment rejecting its plans to roll into a separate company more than 38,000 lawsuits claiming that its talc-based baby...


J&J Ends Mosaico HIV Vaccine Trial on poor Results

27.01.2023 -

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board...


GenScript Raises $224 Million in Fresh Capital

25.01.2023 -

In its third fundraising round in less than two years, Hong Kong-listed globally active CDMO giant GenScript Biotech has netted a fresh $224 million capital injection...


J&J to Pull Talc-based Baby Powder Worldwide

16.08.2022 -

Johnson & Johnson is finally pulling the plug on its iconic talc-based baby powder worldwide.


FDA Restricts Use of J&J Covid Vaccine

13.05.2022 -

US health authorities are restricting the use of the Johnson & Johnson Covid vaccine somewhat belatedly, citing the rare blood clotting issues that have dogged this...